N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions

a technology of n-sulfamoylpiperidineamide and n-sulfamoylpiperidineamide, which is applied in the direction of biocide, drug composition, metabolic disorder, etc., can solve the problems of complex biological mechanisms at the molecular level between insulin resistance and metabolic risk factors, inability to maintain a proper level of glucose, and no well-accepted criteria for diagnosing metabolic syndrom

Inactive Publication Date: 2007-06-28
SOLVAY PHARMA GMBH
View PDF2 Cites 19 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The biologic mechanisms at the molecular level between insulin resistance and metabolic risk factors are not fully understood and appear to be complex.
One group of people at risk for developing metabolic syndrome are those with diabetes who have a defect in insulin action and cannot maintain a proper level of glucose in their blood.
There are no well-accepted criteria for diagnosing the metabolic syndrome.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions
  • N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions
  • N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions

Examples

Experimental program
Comparison scheme
Effect test

example 2

[0113] Urea-analogs (R1═CH2C6H5, R2═CO—NH—C6H5; boc=tert.-butyloxycarbonyl) [0114] 2.1 2.6 g sodium acetate, 5.0 g tert.-butyl-4-aminopiperidine-1-carboxylate, 2.0 ml acetic acid and 2.1 ml benzaldehyde were combined in 200 ml THF and stirred for 4 hrs. at room temperature. After addition of 8.8 g trisacetoxy sodiumborohydride the mixture was stirred for 20 hrs. Then solvent was removed under reduced pressure and the residue was dissolved in a mixture of methyl-tert.-butylether and water. The aqueous layer was made alkaline with NaOH and extracted twice with methyl-tert.-butylether. The combined organic layers were washed three times with 30 ml 0.1N HCl and 5 times with 50 ml 0.1N HCl. Then the aqueous layers were combined and made basic with NaOH, followed by two extractions with methyl-tert.-butylether. The organic layers were washed with water and a saturated solution of NaCl in water, dried over sodium sulfate and then evaporated in vacuum. 4.9 g tert.-butyl 4-(benzylamino)pipe...

example 3

[0121] Substituted amides (R1=CH3; R2=C6H11; boc=tert.-butyloxycarbonyl) [0122] 3.1 2.0 g tert.-butyl 4-oxopiperidine-1-carboxylate, 1.23 g sodium acetate, 0.98 ml acetic acid and 1.56 ml N-methylcyclohexanamine were dissolved in 100 ml THF and stirred for one hour at room temperature. Then 4.25 g trisacetoxy sodiumborohydride were added and the reaction mixture was stirred for 18 hours at room temperature. The reaction mixture was concentrated under reduced pressure and the residue was taken up in a mixture of water and methyl-tert.-butylether. The aqueous layer was made alkaline and extracted twice with methyl-tert.-butylether. Finally, the organic layer was washed 2 times with 0.1N HCl, the aqueous layers were combined and made alkaline (pH 10) by addition of NaOH solution. After extraction (2 times) with methyl-tert.-butylether the organic layer was dried over sodium sulfate and evaporated in vacuum. 1.3 g of oily tert-butyl 4-[cyclohexyl-(methyl)amino]piperidine-1-carboxylate ...

example 4

[0130] Substituted amides (R1═H; R2═C6H11; boc=tert.-butyloxycarbonyl) [0131] 4.1 1.23 g sodium acetate, 2.4 g tert.-butyl-4-aminopiperidine-1-carboxylate, 1.0 ml acetic acid and 1.0 g cyclohexanone were combined in 150 ml THF and stirred for 3 hrs. at room temperature. Then 4.25 g trisacetoxy sodiumborohydride were added and the reaction mixture was stirred for 16 hrs. at room temperature. After concentrating the reaction mixture under reduced pressure the residue was taken up in a mixture of methyl-tert.-butylether and water, which was made alkaline with sodium carbonate to pH 9. The organic layer washed 4 times with 0,1N HCl. Then the aqueous layer was made alkaline with NaOH and extracted twice with methyl-tert.-butylether. The combined organic layers were washed with water and with a saturated solution of NaCl in water, dried over sodium sulfate and then evaporated under reduced pressure, yielding 2.4 g of oily tert-butyl 4-(cyclohexylamino)piperidine-1-carboxylate.

[0132]1H N...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
total volumeaaaaaaaaaa
v/vaaaaaaaaaa
melting pointaaaaaaaaaa
Login to view more

Abstract

The present invention relates to novel N-sulfamoyl-piperidineamides of Formula I and their physiologically acceptable acid addition salts, to pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment of obesity and its concomitant and / or secondary diseases and related or other conditions.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims the benefit under 35 U.S.C. § 119(e) to U.S. provisional patent application Ser. No. 60 / 749,127 filed Dec. 9, 2005, the entire disclosure of which is hereby incorporated in its entirety.BACKGROUND OF THE INVENTION [0002] The present invention relates to novel N-sulfamoyl-piperidineamides and their physiologically acceptable acid addition salts, to pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment of obesity and related conditions. [0003] WO 03 / 088908 discloses N-sulfamoyl-piperidineamides with a specific substitution pattern at the piperidine ring. The compounds of WO03 / 088908 are assumedly useful for treating arrhythmia, IKur-associated conditions, gastrointensinal disorders, diabetes, cognitive disorders, and related conditions. [0004] US2004 / 0167185 describes several N-sulfamoyl-piperidineamides in the area of treating or preventing cancer. [0005] A m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/541A61K31/5377A61K31/496A61K31/454C07D401/02C07D413/02C07D417/02
CPCC07D211/96C07D401/04C07D401/12C07D409/12C07D413/04A61P25/00A61P3/00A61P3/04A61P3/06
Inventor ANTEL, JOCHENFIRNGES, MICHAELSCHOEN, UWEWALDECK, HARALDWURL, MICHAELREICHE, DANIAGREGORY, PETER-COLIN
Owner SOLVAY PHARMA GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap